fluorouracil + mitoxantrone + vinorelbine

This is a combination chemotherapy regimen consisting of three cytotoxic agents—fluorouracil, mitoxantrone, and vinorelbine. Each drug has a distinct mechanism of action targeting cancer cell proliferation: - **Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and function. - **Mitoxantrone** is an anthracenedione that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of both DNA replication and RNA synthesis. - **Vinorelbine** is a semi-synthetic vinca alkaloid that binds to tubulin, inhibiting microtubule assembly during mitosis. This combination has been studied primarily in advanced or metastatic breast cancer patients who have failed previous regimens or relapsed after adjuvant chemotherapy. The regimen aims to improve response rates by combining drugs with complementary mechanisms but can be associated with increased hematologic toxicity (notably neutropenia) compared to single-agent therapy[1][4][6].